Navigation Links
Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
Date:5/16/2010

TOKYO and MELVILLE, N.Y. May 16 /PRNewswire-FirstCall/ -- Astellas Pharma Inc. (TSE: 4503), a global pharmaceutical company, and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP), a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity, today announced that they have entered into a definitive merger agreement under which Astellas will acquire OSI.

Under the terms of the merger agreement, Astellas will increase its offer price to $57.50 per share, which represents a premium of 55% to the closing price for OSI's shares of $37.02 on February 26, 2010, the last trading day before the announcement by Astellas of its tender offer. The boards of directors of both companies have unanimously approved the combination. The all-cash transaction is valued at $4.0 billion on a fully diluted basis.

The combined company creates a world-class oncology platform supporting Astellas' stated growth strategy of becoming a Global Category Leader in Oncology, a high-priority therapeutic area for Astellas. OSI commercializes Tarceva® (erlotinib), a leading cancer medication. OSI's total annual revenues for 2009, as reported in its Form 10-K for the year ended December 31, 2009, were $428 million and operating income was $153 million.

Masafumi Nogimori, President and Chief Executive Officer of Astellas, said, "The merger with OSI prov
'/>"/>

SOURCE Astellas Pharma US, Inc.; OSI Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
2. Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program
3. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
4. CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
5. Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)
6. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
7. CV Therapeutics Statement on Unsolicited Proposal From Astellas
8. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
9. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
10. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
11. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... June 30, 2014, after market close on Thursday, August 14, ... to the market opening on Friday, August 15, 2014, at ... China Standard Time) to review the Company,s financial results and ...
(Date:7/24/2014)... 24, 2014 -- A novel combination of microscopy and ... Energy,s Oak Ridge National Laboratory an unprecedented look at ... physical and electrochemical properties. , The research team ... the surface of a perovskite manganite, a complex material ... avenue to understand surface behavior could benefit researchers who ...
(Date:7/24/2014)... MESA, Calif. , July 24, 2014  Now ... close to home. Rehealth Regenerative Therapies , located ... athletes and other physically active people a new health ... Regardless of age, countless patients suffer from ... sport activities, such as muscle tears, torn rotator cuff, ...
(Date:7/24/2014)... Calif. , July 24, 2014  ECC West ... Denver, Colorado with University College Hospital (UCH) ... a development project to finance, design, construct, and operate ... Nigeria . Under the first of ... prepare scoping documents and funding applications. UCH Ibadan intends ...
Breaking Biology Technology:Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2ORNL study reveals new characteristics of complex oxide surfaces 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... that want the benefits of cutting-edge health care possibilities ... sub-populations need to foster the new science at ... by Nature Publishing Group. , In a special six-paper ... (NRG), researchers from the McLaughlin-Rotman Centre for Global Health ...
... a significant milestone for the growing open source clincial trials ... towards the needs of regulated industry sponsored clinical trials. ... ... 2008 -- Akaza Research announces the availability of OpenClinica 2.5, ...
... ABBOTT PARK, Ill., Sept. 19 Abbott (NYSE:,ABT) will ... 2008, before the market opens., The announcement will ... call at 8 a.m. Central time (9 a.m. Eastern), ... at, http://www.abbottinvestor.com . An archived edition of the call ...
Cached Biology Technology:As personalized, genomic medicine takes off, four developing countries show the way for others 2As personalized, genomic medicine takes off, four developing countries show the way for others 3As personalized, genomic medicine takes off, four developing countries show the way for others 4As personalized, genomic medicine takes off, four developing countries show the way for others 5As personalized, genomic medicine takes off, four developing countries show the way for others 6As personalized, genomic medicine takes off, four developing countries show the way for others 7Akaza Research Releases New Version of OpenClinica Electronic Data Capture (EDC) Software; Targets Industry Clinical Trials 2Akaza Research Releases New Version of OpenClinica Electronic Data Capture (EDC) Software; Targets Industry Clinical Trials 3
(Date:7/25/2014)... Stowers Institute for Medical Research have identified ... found pheromones crucial to triggering the mating process in ... a male mouse detect pheromones that indicate when a ... him know if the female mouse is ovulating and ... to trigger mating. Stowers, researchers believe mice developed this ...
(Date:7/25/2014)... Florida , July 25, 2014 ... more consumers are turning to digital technology for online ... (OTCBB: NXTD), Google Inc. (NASDAQ: GOOG ), ... (NYSE: V ), Apple Inc. (NASDAQ: ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
Breaking Biology News(10 mins):It takes two to court 2It takes two to court 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... A research team led by scientists at the Virginia Bioinformatics ... mechanism that allows dangerous fungal microbes to infect plants and ... of new intervention strategies to protect plant, and even some ... in the July 23 edition of the journal Cell ...
... "Many people," says Dr. Eeva Karjalainen, of the Finnish Forest ... out in nature. But not many of us know that ... nature." Forests and other natural, green settings ... and increase overall happiness. Forest visits may also strengthen our ...
... in Chinese . , Formation of new ... sustained tumor growth and cancer metastasis. Recently, clinically available ... been available to improve patient survival in some cancer ... using nonsurgical methods would greatly complement current therapies and ...
Cached Biology News:Scientists discover how deadly fungal microbes enter host cells 2Noninvasive MR imaging of blood vessel growth in tumors using nanosized contrast agents 2Noninvasive MR imaging of blood vessel growth in tumors using nanosized contrast agents 3
... Imaging System, Professional Package Superior Protein ... Range: The ProXPRESS 2D Proteomic Imaging System ... for both proteomic and general life science ... enabling the use of all dyes in ...
... Corning single use spatulas have been ... samples. They are for those interested in ... reusable spatulas. Each spatula is individually packaged, ... CLS number is a new product number, ...
... digital valve, just 8 mm in width. ... in a single glass-reinforced, PBT (Polybutylene Terephthalate) molded ... width. , Meets a range of pressure requirements ... Satisfies a 0.016 sccm leakage specification (0.2 sccm ...
... FilterMate is a compact, versatile system that ... 96- or 24-well microplates into a solid ... liquid scintillation and gamma counter. The FilterMate ... for applications such as cell proliferation, receptor ...
Biology Products: